Hematologic Cancers

Galecto has priced a public offering of common stock, aiming to raise approximately $275 million before expenses. The offering includes an option for underwriters to purchase additional shares, potentially increasing total proceeds to around $317 million. This capital infusion will support the biopharmaceutical company’s development of innovative therapies for blood cancers, including its myeloproliferative neoplasm portfolio and acute myeloid leukemia treatments. The offering is expected to close around February 12, 2026.